Published in Cancer Weekly, December 30th, 2003
The research team, headed by Thomas Habermann, MD, of the Eastern Cooperative Oncology Group, Boston, concluded that the addition of rituximab to the CHOP regimen as a first-line treatment did not...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.